01/21.Patient Counselling Information -(2021) - No.1. Vericiguat -(VERQUVO) -(Jan 2021)
Drug Name:
01/21.Patient Counselling Information -(2021) - No.1. Vericiguat -(VERQUVO) -(Jan 2021)
List Of Brands:
Indication Type Description:
Drug Interaction:
Vericuguat (VERGUVO) -(Jan 2021)
PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Medication Guide). Dosing Instructions If a dose is missed, it should be taken as soon as the patient remembers on the same day of the missed dose.
Patients should not take two doses of VERQUVO on the same day.
Embryo-Fetal Toxicity - Advise pregnant women and females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy.
Advise females of reproductive potential to use effective contraception during treatment with VERQUVO and for one month after the final dose
Pregnancy- Advise women who are exposed to VERQUVO during pregnancy to report their pregnancy to their healthcare provider. [See Use in Specific Populations (8.1)]. Lactation
Advise women not to breastfeed during treatment with VERQUVO
Manufactured by:
Bayer AG
Leverkusen, Germany
For patent information: www.merck.com/product/patent/home.html
Copyright © 2021 Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc.
Indication:
U.S. FDA APPROVED DRUGS DURING 2020
Sr.No- 1
Name of the Drug- VERQUVO
Active Ingredient - Veriguat
Pharmacological Classification-
To treat chronic heart failure
Date of Approval- 1/1/2021